Shilpa Medicare strengthens on getting USFDA’s approval for Bortezomib for Injection

09 Apr 2019 Evaluate

Shilpa Medicare is currently trading at Rs. 335.00, up by 3.20 points or 0.96% from its previous closing of Rs. 331.80 on the BSE.

The scrip opened at Rs. 338.95 and has touched a high and low of Rs. 339.80 and Rs. 333.00 respectively. So far 1277 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 546.95 on 14-Sep-2018 and a 52 week low of Rs. 328.05 on 02-Apr-2019.

Last one week high and low of the scrip stood at Rs. 339.80 and Rs. 330.25 respectively. The current market cap of the company is Rs. 2723.00 crore.

The promoters holding in the company stood at 53.80%, while Institutions and Non-Institutions held 32.35% and 13.85% respectively.

Shilpa Medicare has received the US Food and Drug Administration’s (USFDA) tentative approval for its ANDA, Bortezomib for Injection, 3.5mg/vial. Bortezomib for Injection, 3.5mg/vial is a generic equivalent of reference listed drug (RLD), VELCADE used in the treatment of patients with multiple myeloma and Mantle Cell Lymphoma as recommended in the label approved by USFDA.
 
According to IQVIA MAT Q4 2018 data, the US market for Bortezomib for Injection 3.5 mg/vial is approximately $609 million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

323.45 -2.50 (-0.77%)
17-Dec-2025 11:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.30
Dr. Reddys Lab 1276.00
Cipla 1493.60
Zydus Lifesciences 917.00
Lupin 2116.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×